{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:53Z","timestamp":1793774813260,"version":"4.6.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009561","name":"American Partnership for Eosinophilic Disorders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.mayocp.2023.02.013","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T06:00:37Z","timestamp":1688536837000},"page":"1054-1070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["HES and EGPA"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-0079","authenticated-orcid":false,"given":"Paneez","family":"Khoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Akuthota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namhee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Steinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Roufosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2023.02.013_bib1","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in health and disease: a state-of-the-art review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.mayocp.2023.02.013_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of eosinophils to human health and disease","volume":"15","author":"Klion","year":"2020","journal-title":"Ann Rev Pathol"},{"issue":"4","key":"10.1016\/j.mayocp.2023.02.013_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pop.2016.07.010","volume":"43","author":"Kovalszki","year":"2016","journal-title":"Eosinophilia. Prim Care"},{"issue":"10","key":"10.1016\/j.mayocp.2023.02.013_bib4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.013_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/all.12088","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art","volume":"68","author":"Vaglio","year":"2013","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.mayocp.2023.02.013_bib8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.leukres.2012.12.016","article-title":"Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature","volume":"37","author":"Podjasek","year":"2013","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.013_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.mayocp.2023.02.013_bib10","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"issue":"5 suppl 1","key":"10.1016\/j.mayocp.2023.02.013_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/abd1806-4841.20175522","article-title":"Cutaneous manifestations of Churg-Strauss syndrome: key to diagnosis","volume":"92","author":"Marques","year":"2017","journal-title":"An Bras Dermatol"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/acr.22686","article-title":"Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"68","author":"Durel","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.mayocp.2023.02.013_bib14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40265-018-0920-8","article-title":"Treatment of eosinophilic granulomatosis with polyangiitis: a review","volume":"78","author":"Raffray","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.mayocp.2023.02.013_bib15","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3389\/fimmu.2020.01765","article-title":"Eosinophilia associated with CD3(\u2013)CD4(+) T cells: characterization and outcome of a single-center cohort of 26 patients","volume":"11","author":"Carpentier","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.mayocp.2023.02.013_bib16","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA\u2013positive myeloid neoplasm with eosinophilia: data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.mayocp.2023.02.013_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fmed.2017.00216","article-title":"(A critical appraisal of) classification of hypereosinophilic disorders","volume":"4","author":"Kahn","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10.1016\/j.mayocp.2023.02.013_bib18","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1398-9995.2012.02873.x","article-title":"Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome","volume":"67","author":"Khoury","year":"2012","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.013_bib19","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.013_bib20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaip.2020.07.038","article-title":"Antineutrophil Cytoplasmic Antibodies and Organ-Specific Manifestations in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis","volume":"9","author":"Chang","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.mayocp.2023.02.013_bib21","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202005-1628SO","article-title":"International consensus on ANCA testing in eosinophilic granulomatosis with polyangiitis","author":"Moiseev","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.013_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.chest.2020.09.247","article-title":"Approach to eosinophilia presenting with pulmonary symptoms","volume":"159","author":"Rosenberg","year":"2021","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.013_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ijlh.12955","article-title":"How I investigate Eosinophilia","volume":"41","author":"Larsen","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2023.02.013_bib24","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jaip.2018.04.030","article-title":"Consultation for elevated blood eosinophils: clinical presentations, high value diagnostic tests, and treatment options","volume":"6","author":"Khoury","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.mayocp.2023.02.013_bib25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.mayocp.2023.02.013_bib27","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A\u00a0tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.mayocp.2023.02.013_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.41982","article-title":"American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib30","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.jaip.2021.01.030","article-title":"CD3(\u2013)CD4(+) lymphocytic variant hypereosinophilic syndrome: diagnostic tools revisited","volume":"9","author":"Carpentier","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.013_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib32","first-page":"989","article-title":"Can ANCA differentiate eosinophilic granulomatosis with polyangiitis (Churg-Strauss) from idiopathic hypereosinophilic syndrome?","volume":"31","author":"Zwerina","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.013_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.013_bib34","first-page":"40","article-title":"Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma","volume":"37","author":"Pagnoux","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.mayocp.2023.02.013_bib35","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jaip.2018.10.002","article-title":"C-Reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis","volume":"7","author":"Leurs","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.mayocp.2023.02.013_bib36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.alit.2022.05.011","article-title":"Radiological significance of mediastinal lymphadenopathy in eosinophilic granulomatosis with polyangiitis","volume":"71","author":"Sasaki","year":"2022","journal-title":"Allergol Int"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121737","article-title":"Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"10","author":"Dejaco","year":"2015","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.mayocp.2023.02.013_bib38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.mayocp.2023.02.013_bib39","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.jaip.2020.04.069","article-title":"Symptom assessment in hypereosinophilic syndrome: toward development of a patient-reported outcomes tool","volume":"8","author":"Kovacs","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ehm.12.14","article-title":"Clinical management of the hypereosinophilic syndromes","volume":"5","author":"Cogan","year":"2012","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.013_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/1744666X.2018.1425142","article-title":"Imatinib for the treatment of hypereosinophilic syndromes","volume":"14","author":"Helbig","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"10.1016\/j.mayocp.2023.02.013_bib42","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.013_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-005-1084-7","article-title":"Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature","volume":"85","author":"M\u00fcller","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.mayocp.2023.02.013_bib44","unstructured":"FDA. Imatinib Mesylate (Gleevec) Prescribing Information. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021588s047lbl.pdf Access Date, January 26, 2023"},{"issue":"7","key":"10.1016\/j.mayocp.2023.02.013_bib45","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","article-title":"Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2023.02.013_bib46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.013_bib47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.leukres.2011.09.026","article-title":"Use of pegylated interferon in hypereosinophilic syndrome","volume":"36","author":"Butterfield","year":"2012","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MD.0b013e31815d108c","article-title":"Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics","volume":"86","author":"Dahabreh","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.mayocp.2023.02.013_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.631055","article-title":"New insights into novel therapeutic targets in ANCA-associated vasculitis","volume":"12","author":"Nozaki","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.013_bib50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.013_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000905","article-title":"Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Teixeira","year":"2019","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib52","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a European Collaborative Study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.mayocp.2023.02.013_bib53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2020.06.017","article-title":"Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?","volume":"136","author":"Houot","year":"2020","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib54","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"20","key":"10.1016\/j.mayocp.2023.02.013_bib55","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2023.02.013_bib56","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2023.02.013_bib57","unstructured":"PMDA. Mepolizumab (Nucala) Prescribing Information (Japan). 2020. https:\/\/gskpro.com\/ja-jp\/products-info\/nucala\/index\/ Access Date 26 January, 2023"},{"key":"10.1016\/j.mayocp.2023.02.013_bib58","unstructured":"EMA. Mepolizumab (Nucala) Summary of Product Characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf Access Date January 26, 2023"},{"key":"10.1016\/j.mayocp.2023.02.013_bib59","unstructured":"FDA. Mepolizumab (Nucala) Prescribing Information. 2022. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF Access Date January 26. 2023"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib60","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2004.08.027","article-title":"Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700","volume":"114","author":"Kim","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.mayocp.2023.02.013_bib61","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.mayocp.2023.02.013_bib62","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib63","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.mayocp.2023.02.013_bib64","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.mayocp.2023.02.013_bib65","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2023.02.013_bib66","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib67","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib69","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib68","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"suppl 10","key":"10.1016\/j.mayocp.2023.02.013_bib70","article-title":"Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: a double-blind, randomized, controlled trial [abstract]","volume":"73","author":"Terrier","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib71","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaci.2012.07.027","article-title":"Novel targeted therapies for eosinophilic disorders","volume":"130","author":"Wechsler","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib72","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.iac.2007.07.004","article-title":"Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders","volume":"27","author":"Ackerman","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.mayocp.2023.02.013_bib73","unstructured":"FDA. Rezslizumab (Cinqaero) Prescribing Information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/0761033s010lbl.pdf Access Date January 26, 2023"},{"issue":"4","key":"10.1016\/j.mayocp.2023.02.013_bib74","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.013_bib75","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.mayocp.2023.02.013_bib76","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.013_bib77","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"26","key":"10.1016\/j.mayocp.2023.02.013_bib78","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2023.02.013_bib79","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.mayocp.2023.02.013_bib80","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1016\/j.jaip.2020.06.052","article-title":"Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab","volume":"8","author":"Galant-Swafford","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.013_bib81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13223-021-00639-x","article-title":"Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi","volume":"18","author":"Adachi","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"10","key":"10.1016\/j.mayocp.2023.02.013_bib82","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1016\/j.jaip.2021.06.033","article-title":"Effect of dupilumab treatment in a severe asthma patient with EGPA","volume":"9","author":"Matucci","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.013_bib83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.mayocp.2023.02.013_bib84","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.healun.2014.02.023","article-title":"Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)","volume":"33","author":"Groh","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.013_bib85","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/asheducation-2018.1.326","article-title":"Hypereosinophilic syndrome: approach to treatment in the era of precision medicine","volume":"2018","author":"Klion","year":"2018","journal-title":"Hematology Am Soc Hemtol Educ Program"},{"key":"10.1016\/j.mayocp.2023.02.013_bib86","article-title":"Cardiac involvement in eosinophilic granulomatosis with polyangiitis: a retrospective study in the Chinese population","volume":"7","author":"Chen","year":"2020","journal-title":"Front Med (Lausanne)"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619623000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619623000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:39:46Z","timestamp":1758418786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619623000721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0025619623000721"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2023.02.013","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HES and EGPA","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2023.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}